Philippe LESTAEVEL

Dr. Philippe LESTAEVEL


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Toxicology
Verified
Journal Article
Closed access
CDCéline Dinocourt
Céline Dinocourt
MLMarie Legrand
Marie Legrand
IDIsabelle Dublineau
Isabelle Dublineau
PLPhilippe LESTAEVEL
Philippe LESTAEVEL

1 September 2005 in Toxicology
Verified
Journal Article
Closed access
PLPhilippe LESTAEVEL
Philippe LESTAEVEL
PHP. Houpert
P. Houpert
CBC. Bussy
C. Bussy
BDB. Dhieux
B. Dhieux
PGP. Gourmelon
P. Gourmelon
FPF. Paquet
F. Paquet

1 April 2009 in Toxicology
Verified
Journal Article
Closed access
PLPhilippe LESTAEVEL
Philippe LESTAEVEL
ERE. Romero
E. Romero
BDB. Dhieux
B. Dhieux
HSH. Ben Soussan
H. Ben Soussan
HBH. Berradi
H. Berradi
PGP. Gourmelon
P. Gourmelon

1 January 2016 in NeuroToxicology
Verified
Journal Article
Closed access
MLM. Legrand
M. Legrand
CEC. Elie
C. Elie
JSJ. Stefani
J. Stefani
NLN.F Lorès
N.F Lorès
CCC. Culeux
C. Culeux
CDCéline Dinocourt
Céline Dinocourt

18 December 2015 in BMC Neurology
Verified
Journal Article
Open access
PDF file
TDThomas Durand
Thomas Durand
Sophie JacobSophie Jacob
Sophie Jacob
LLLaura Lebouil
Laura Lebouil
HDHassen Douzane
Hassen Douzane
PLPhilippe LESTAEVEL
Philippe LESTAEVEL
MBMarie-Odile Bernier
Marie-Odile Bernier
Radiotherapy is one of the most important treatments of primary and metastatic brain tumors. Unfortunately, it can involve moderate to severe complications among which leukoencephalopathy is very frequent and implies cognitive deficits such as memory, attention and executive dysfunctions. However, the incidence of this complication is not well established and the risk factors and process are poorly understood. The main objective of the study is to improve knowledge on radio-induced leukoencephalopathy based on pluridisciplinar approaches combining cognitive, biologic, imagery and dosimetric investigations. The EpiBrainRad study is a prospective cohort study including newly diagnosed high grade gliomas patients treated by radiotherapy and concomitant-adjuvant temozolomide chemotherapy. Patients are included between their surgery and first day of radio-chemotherapy, and the follow-up lasts for 3 years after treatment. Cognitive functioning assessments, specific blood biomarkers measures and magnetic resonance imagery are performed at different moment during the follow-up, and a specific dosimetric assessment of organs involved in the beam fields is performed. Firstly, leukoencephalopathy incidence rate will be estimated in this population. Secondly, correlations between cognitive impairments and dosimetry, biomarkers ranges and anomalies on imagery will be analyzed in order to better understand the onset and evolution of cognitive decrement associated with radiotherapy. Furthermore, a new cognitive test, quickly and easily performed, will be studied to determine its sensibility to detect leukoencephalopathy decrement. With an original multidisciplinary approach, the EpiBrainRad study aims to improve knowledge on radio-induced leukoencephalopathy in order to improve its early diagnosis and prevention. The main challenge is to preserve quality-of-life after cancer treatments which imply to study the incidence of radiation-induced complications and their associated risk factors. NCT02544178

CDCéline Dinocourt
Céline Dinocourt
CCCécile Culeux
Cécile Culeux
MLMarie Legrand
Marie Legrand
CEChristelle Elie
Christelle Elie
PLPhilippe LESTAEVEL
Philippe LESTAEVEL
Uranium exposure leads to cerebral dysfunction involving for instance biochemical, neurochemical and neurobehavioral effects. Most studies have focused on mechanisms in uranium-exposed adult animals. However, recent data on developing animals have shown that the developing brain is also sensitive to uranium. Models of uranium exposure during brain development highlight the need to improve our understanding of the effects of uranium. In a model in which uranium exposure began from the first day of gestation, we studied the neurobehavioral consequences as well as the progression of hippocampal neurogenesis in animals from dams exposed to uranium. Our results show that 2-month-old rats exposed to uranium from gestational day 1 displayed deficits in special memory and a prominent depressive-like phenotype. Cell proliferation was not disturbed in these animals, as shown by 5-bromo-2′deoxyuridine (BrdU)/neuronal specific nuclear protein (NeuN) immunostaining in the dentate gyrus. However, in some animals, the pyramidal cell layer was dispersed in the CA3 region. From our previous results with the same model, the hypothesis of alterations of neurogenesis at prior stages of development is worth considering, but is probably not the only one. Therefore, further investigations are needed to correlate cerebral dysfunction and its underlying mechanistic pathways.